Solveat and CBC collaborate on botanical-enhanced functional soft drinks
SOLVEAT has announced an investment-based joint development and commercial agreement with The Central Bottling Company, Ltd. (CBC Group) to develop functional beverages incorporating the startup’s patented botanical formulations. The long-term collaboration will focus on creating soft drinks targeting health categories including metabolic support and blood sugar control.
Under the partnership, SOLVEAT will work with CBC’s subsidiary Gat Foods to develop a new line of functional beverages. CBC will handle manufacturing and commercialisation, providing SOLVEAT access to Gat Foods’ global customer network. Research and development will take place at SOLVEAT facilities in collaboration with CORE – CBC Group’s Open Innovation Centre – and clinicians from Sheba Medical Center.
Microencapsulation technology addresses formulation challenges
SOLVEAT’s approach centres on a proprietary phyto-delivery platform that integrates clinically validated herbal compositions into food products whilst maintaining sensory qualities. The company’s microencapsulation technology addresses a key technical challenge in botanical-enhanced products.
“Botanicals naturally bring bold flavours with bitter undertones which makes infusing them into food and drink challenging,” explains Zacki Nudelman, PhD, Co-founder, CBO, and Scientific Affairs Officer for SOLVEAT. “We apply a proprietary multi-ingredients microencapsulation technology that not only effectively masks any bitterness but also is heat resistant, preserving the functional compounds, maintaining their bioactivity, and allowing controlled release.”
The technology enables encapsulation of complete herbal compositions containing multiple botanicals, rather than single ingredients. According to the company, this provides compatibility across both liquid and solid food applications.
Clinical validation and commercial readiness
SOLVEAT’s lead functional composition targets blood sugar balance and is scheduled for pilot sales in early 2026. The formulation is currently undergoing clinical assessment with an undisclosed health organisation. The company reports additional ingredients for immune support and metabolic wellness are in development.
The platform operates at industrial scale through contract manufacturers, with capacity to produce approximately 600 tonnes of ingredients annually.
“We are grateful for the opportunity to team up with such an influential player in the global beverage arena,” says Udi Peretz, CEO and Co-founder of SOLVEAT. “Our shared vision is to introduce a new generation of soft drinks that are as delightfully quenching as this category is meant to be, yet with unique wellness value. We will create a line of still beverages that not only address metabolic issues but deliver wellness benefits within an enjoyable consumer experience.”
Market context
Consumer demand for functional beverages continues to grow. The International Food Information Council (IFIC) reports that 76% of consumers believe their food and beverage choices impact emotional and mental wellbeing. The Institute of Food Technologists (IFT) ranked ‘food as medicine’ among the top five of 25 leading food and beverage trends for 2025.
SOLVEAT showcased its blood sugar-balancing botanical-infused chocolate at the FoodTech Congress in Barcelona on 4-5 November 2025.
For more information, visit: www.solveat-health.com
